Book contents
- Genome Editing and Engineering
- Genome Editing and Engineering
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Part I Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and Regulatory Networks
- Part II Genome Editing in Model Organisms
- Part III Technology Development and Screening
- Part IV Genome Editing in Stem Cells and Regenerative Biology
- Part V Genome Editing in Disease Biology
- Part VI Legal (Intellectual Property) and Bioethical Issues of Genome Editing
- Index
- Plate Section (PDF Only)
- References
Part VI - Legal (Intellectual Property) and Bioethical Issues of Genome Editing
Published online by Cambridge University Press: 30 July 2018
Edited by
Foreword by
Book contents
- Genome Editing and Engineering
- Genome Editing and Engineering
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Preface
- Part I Biology of Endonucleases (Zinc-Finger Nuclease, TALENs and CRISPRs) and Regulatory Networks
- Part II Genome Editing in Model Organisms
- Part III Technology Development and Screening
- Part IV Genome Editing in Stem Cells and Regenerative Biology
- Part V Genome Editing in Disease Biology
- Part VI Legal (Intellectual Property) and Bioethical Issues of Genome Editing
- Index
- Plate Section (PDF Only)
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Genome Editing and EngineeringFrom TALENs, ZFNs and CRISPRs to Molecular Surgery, pp. 421 - 463Publisher: Cambridge University PressPrint publication year: 2018
References
References
Haeussler, M, Concordet, J. 2016. Genome editing with CRISPR-Cas9: can it get any better? J Genet Genom 43(5): 239–250.CrossRefGoogle ScholarPubMed
Jinek, M, Chylinski, K, Fonfara, I, et al. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816–821.CrossRefGoogle ScholarPubMed
Leahy-Smith America Invents Act. 2011. One Hundred Twelfth Congress of the United States of America, Public Law 112–29, September 16, 2011, 125 Stat 284.Google Scholar
Ledford, H. 2016. Bitter fight over CRISPR patent heats up. Nature 529: 265.CrossRefGoogle ScholarPubMed
Noonan, KE. 2016. CRISPR interference declared. Patent Docs. www.patentdocs.org/2016/01/crispr-interference-declared.html (accessed November 2017).Google Scholar
Sherkow, J. 2015. The CRISPR patent interference showdown is on: how did we get here and what comes next? Stanford Law School, Law and Biosciences Blog. https://law.stanford.edu/2015/12/29/the-crispr-patent-interference-showdown-is-on-how-did-we-get-here-and-what-comes-next/ (accessed November 2017).Google Scholar
Sibley, A, Sparks, R. 2009. The difficulty of determining joint inventorship, especially with regard to novel chemical compounds and their applications. Loyola Law Technol Annu 8(1): 44–62.Google Scholar
Sparks, R. 2008. Performing a preliminary assessment of patentability for a new invention: guidelines for non-patent lawyers. Int In-House Counsel J 2(5): 816–827.Google Scholar
Sparks, R. 2009. Unintended negative consequences of joint ownership of a patent. Int In-House Counsel J 3(9): 1411–1420.Google Scholar
Sparks, R, Park, S, Paschall, C. 2015. Recent patent legislation and court decisions in the United States: impact on validity of patents and on obtaining, licensing, and enforcing patents. Int In-House Counsel J 8(31):, 3369–3380.Google Scholar
Zhang, F, Zetsche, B, Slaymaker, I, Gootenberg, J, Abudayyeh, O. 2016. Novel CRISPR Enzymes and Systems. US Patent Application Number 14/975,085.Google Scholar
References
Araki, M, Ishii, T. 2016. Providing appropriate risk information on genome editing for patients. Trends Biotechnol 34: 86–90.CrossRefGoogle ScholarPubMed
Barbour, V. 2000. The balance of risk and benefit in gene-therapy trials. Lancet 355: 384.CrossRefGoogle ScholarPubMed
Barritt, JA, Brenner, CA, Malter, HE, Cohen, J. 2001a. Mitochondria in human offspring derived from ooplasmic transplantation. Hum Reprod 16: 513–516.CrossRefGoogle ScholarPubMed
Barritt, JA, Brenner, CA, Malter, HE, Cohen, J. 2001b. Rebuttal: interooplasmic transfers in humans. Reprod Biomed Online 3: 47–48.CrossRefGoogle ScholarPubMed
Chervyakov, YV, Staroverov, IN, Vlasenko, ON, et al. 2016. [Remote results of treatment of patients with chronic lower-limb ischaemia by means of indirect revascularization and gene therapy]. Angiol Sosud Khir 22: 29–34, 36–37.Google ScholarPubMed
Colombo, N, Carinelli, S, Colombo, A, et al. 2012. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl. 7): vii27–vii32.CrossRefGoogle ScholarPubMed
Cox, DB, Platt, RJ, Zhang, F. 2015. Therapeutic genome editing: prospects and challenges. Nat Med 21: 121–131.CrossRefGoogle ScholarPubMed
Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132–3142.CrossRefGoogle ScholarPubMed
Hawes, SM, Sapienza, C, Latham, KE. 2002. Ooplasmic donation in humans: the potential for epigenic modifications. Hum Reprod 17: 850–852.CrossRefGoogle ScholarPubMed
Hsu, PD, Lander, ES, Zhang, F. 2014. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157: 1262–1278.CrossRefGoogle Scholar
Hutter, G, Nowak, D, Mossner, M, et al. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360: 692–698.CrossRefGoogle ScholarPubMed
Ishii, T. 2014. Potential impact of human mitochondrial replacement on global policy regarding germline gene modification. Reprod Biomed Online 29: 150–155.CrossRefGoogle ScholarPubMed
Ishii, T. 2015a. Germ line genome editing in clinics: the approaches, objectives and global society. Brief Funct Genom 16: 46–56.CrossRefGoogle ScholarPubMed
Ishii, T. 2015b. Germline genome-editing research and its socioethical implications. Trends Mol Med 21: 473–481.CrossRefGoogle ScholarPubMed
Joung, JK. 2015. Unwanted mutations: standards needed for gene-editing errors. Nature 523: 158.CrossRefGoogle ScholarPubMed
Joung, JK, Sander, JD. 2013. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14: 49–55.CrossRefGoogle Scholar
Kang, X, He, W, Huang, Y, et al. 2016. Introducing precise genetic modifications into human 3 PN embryos by CRISPR/Cas-mediated genome editing. J Assist Reprod Genet 33: 581–588.CrossRefGoogle Scholar
Kimmelman, J. 2007. Stable ethics: enrolling non-treatment-refractory volunteers in novel gene transfer trials. Mol Ther 15: 1904–1906.CrossRefGoogle ScholarPubMed
Kimmelman, J. 2008. The ethics of human gene transfer. Nat Rev Genet 9: 239–244.CrossRefGoogle ScholarPubMed
Klug, A. 2010. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem 79: 213–231.CrossRefGoogle ScholarPubMed
Li, AP. 2001. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 6: 357–366.CrossRefGoogle ScholarPubMed
Li, Y, Li, B, Li, CJ, Li, LJ. 2015. Key points of basic theories and clinical practice in rAd-p53 (Gendicine) gene therapy for solid malignant tumors. Expert Opin Biol Ther 15: 437–454.CrossRefGoogle ScholarPubMed
Liang, P, Xu, Y, Zhang, X, et al. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6: 363–372.CrossRefGoogle ScholarPubMed
Qasim, W, Jal Amrolia, S, Samarasinghe, S, et al. 2015. First clinical application of talen engineered universal CAR19 T cells in B-ALL. Blood 126: 2046.CrossRefGoogle Scholar
Sadelain, M, Papapetrou, EP, Bushman, FD. 2012. Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 12: 51–58.CrossRefGoogle Scholar
Sampino, S, Zacchini, F, Swiergiel, AH, et al. 2014. Effects of blastomere biopsy on post-natal growth and behavior in mice. Hum Reprod 29: 1875–1883.CrossRefGoogle ScholarPubMed
Schimmer, J, Breazzano, S. 2016. Investor outlook: rising from the ashes; GSK’s European approval of Strimvelis for ADA-SCID. Hum Gene Ther Clin Dev 27: 57–61.CrossRefGoogle ScholarPubMed
Taylor, TH, Gitlin, SA, Patrick, JL, et al. 2014. The origin, mechanisms, incidence and clinical consequences of chromosomal mosaicism in humans. Hum Reprod Update 20: 571–581.CrossRefGoogle ScholarPubMed
Tebas, P, Stein, D, Tang, WW, et al. 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370: 901–910.CrossRefGoogle ScholarPubMed
Watanabe, N, Yano, K, Tsuyuki, K, Okano, T, Yamato, M. 2015. Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. Mol Ther Methods Clin Dev 2: 14066.CrossRefGoogle ScholarPubMed
Whittaker, AM. 2011. Reproduction opportunists in the new global sex trade: PGD and non-medical sex selection. Reprod Biomed Online 23: 609–617.CrossRefGoogle ScholarPubMed
Yu, Y, Wu, J, Fan, Y, et al. 2009. Evaluation of blastomere biopsy using a mouse model indicates the potential high risk of neurodegenerative disorders in the offspring. Mol Cell Proteomics 8: 1490–1500.CrossRefGoogle ScholarPubMed
Zhang, JEA. 2003. Pregnancy derived from human nuclear transfer. Fertil Steril 80: 56.CrossRefGoogle Scholar
References
Boeke, JD, Church, G, Hessel, A, et al. 2016. Genome engineering: the Genome Project-Write. Science 353: 126–127.CrossRefGoogle ScholarPubMed
Brazier, M. 1999. Regulating the reproduction business? Med Law Rev 7: 166–193.CrossRefGoogle ScholarPubMed
Callaway, E. 2016a. Plan to synthesize human genome triggers mixed response. Nature 534: 163.CrossRefGoogle ScholarPubMed
Callaway, E. 2016b. Second Chinese team reports gene editing in human embryos. Nature 530: 18.CrossRefGoogle Scholar
Chan, S, Donovan, PJ, Douglas, T, et al. 2015. Genome editing technologies and human germline genetic modification: the Hinxton Group Consensus Statement. Am J Bioeth 15: 42–47.CrossRefGoogle ScholarPubMed
Chan, S, Harris, J. 2006. The ethics of gene therapy. Curr Opin Mol Ther 8: 377–383.Google ScholarPubMed
Chan, S, Medina Arellano, M-D-J. 2016. Genome editing and international regulatory challenges: lessons from Mexico. Ethics Med Publ Health 2(3): 426–434.CrossRefGoogle Scholar
Endy, D, Zoloth, L. 2016. Should we synthesise a human genome? Cosmos, 12 May, https://cosmosmagazine.com/society/should-we-synthesise-a-human-genome (accessed August 2016).Google Scholar
Ginn, SL, Alexander, IE, Edelstein, ML, Abedi, MR, Wixon, J. 2013. Gene therapy clinical trials worldwide to 2012: an update. J Gene Med 5: 65–77.CrossRefGoogle Scholar
Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132–3142.CrossRefGoogle ScholarPubMed
Holm, S. 1993. The spare embryo: a red herring in the embryo experimentation debate. Health Care Anal 1: 63–66; discussion 67–68.CrossRefGoogle ScholarPubMed
Human Fertilisation and Embryology Act 1990. www.legislation.gov.uk/ukpga/1990/37/contents (accessed November 2017).Google Scholar
Isasi, RM. 2009. Policy interoperability in stem cell research: demystifying harmonization. Stem Cell Rev 5: 108–115.CrossRefGoogle ScholarPubMed
Isasi, RM, Knoppers, BM. 2006. Mind the gap: policy approaches to embryonic stem cell and cloning research in 50 countries. Eur J Health Law 13: 9–25.CrossRefGoogle ScholarPubMed
Kang, X, He, W, Huang, Y, et al. 2016. Introducing precise genetic modifications into human 3 PN embryos by CRISPR/Cas-mediated genome editing. J Assist Reprod Genet 33: 581–588.CrossRefGoogle Scholar
Kimmelman, J. 2008. The ethics of human gene transfer. Nat Rev Genet 9: 239–244.CrossRefGoogle ScholarPubMed
Lanphier, E, Urnov, F, Haecker, SE, Werner, M, Smolenski, J. 2015. Don’t edit the human germ line. Nature 519: 410–411.CrossRefGoogle ScholarPubMed
Liang, P, Xu, Y, Zhang, X, et al. 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6: 363–372.CrossRefGoogle ScholarPubMed
Marshall, E. 1999. Gene therapy death prompts review of adenovirus vector. Science 286: 2244–2245.CrossRefGoogle ScholarPubMed
Pollack, A. 2016. Scientists talk privately about creating a synthetic human genome. New York Times, 13 May, www.nytimes.com/2016/05/14/science/synthetic-human-genome.html (accessed August 2016).Google Scholar
Reardon, S. 2016. US panel greenlights creation of male “three-person” embryos. Nature 530: 142.CrossRefGoogle ScholarPubMed
Savulescu, J. 2001. Harm, ethics committees and the gene therapy death. J Med Ethics 27: 148–150.CrossRefGoogle ScholarPubMed
UNESCO. 1998. Universal Declaration on the Human Genome and Human Rights. http://unesdoc.unesco.org/images/0012/001229/122990eo.pdf (accessed November 2017).Google Scholar
Wilson, D. 2011. Creating the “ethics industry”: Mary Warnock, in vitro fertilization and the history of bioethics in Britain. Biosocieties 6: 121–141.CrossRefGoogle Scholar